UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

About 5.5 million Americans live with dementia, requiring US$53 billion in annual medical spending on doctor visits, ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

The benefits from 2 new Alzheimer’s treatments remain too small to justify the additional cost to the NHS, an independent NICE c ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...